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        Introduction 
  Werner syndrome (WS) is a human autosomal recessive disorder. 
Affected individuals prematurely exhibit many age-related 
pathologies as well as a high predisposition for cancer develop-
ment ( Martin and Oshima, 2000 ;  Oshima, 2000 ). The gene mutated 
in WS,   WRN  , encodes a nuclear protein that is a member of the 
RecQ family of DNA helicases and possesses two enzymatic 
activities: an ATP-dependent 3     –  5      DNA unwinding activity 
(  Gray et al., 1997  ;   Suzuki et al., 1997  ) and a 3     –  5      exonuclease 
activity residing in the amino-terminal region ( Huang et al., 1998 ). 
Cultured cells derived from WS patients show a wide genomic 
instability manifested as spontaneous chromosomal abnormali-
ties and large deletions in many genes (  Salk, 1985  ;   Gebhart et al., 
1988  ;   Fukuchi et al., 1989  ), which may represent an important 
determinant of the increased risk of cancer (  Goto et al., 1996  ; 
  Moser et al., 2000  ;   van Brabant et al., 2000  ). RecQ helicase family 
members are implicated in several biochemical processes such 
as DNA replication, recombination, and repair but the precise 
molecular function of WRN is not well elucidated. Also, the 
functional signifi  cance of each WRN biochemical activity and 
whether loss of one or both leads to WS pathogenesis is not fully 
understood. In vitro studies have shown that forked duplexes re-
sembling DNA structures arising during replication, recombination, 
and repair are resolved by the coordinated action of WRN activ-
ities (  Shen and Loeb, 2000  ;   Opresko et al., 2004  ). Interestingly, 
recombination requires both WRN activities, whereas single 
helicase or exonuclease activity is suffi  cient to protect cells against 
toxic insults (  Swanson et al., 2004  ). Other studies indicated that 
WRN helicase activity has a role in the prevention of telomere 
dysfunction (  Bai and Murnane, 2003  ;   Cheng et al., 2004  ). 
  Mounting evidence strongly supports the idea that WRN 
may play a critical role in the rescue of stalled replication forks. 
First, S phase prolongation is observed in WS cells together 
with extreme sensitivity to drugs that block replication fork 
progression (  Poot et al., 1999, 2001  ;   Pichierri et al., 2000a  ,  b  ). 
Second, WRN shows a great substrate preference toward com-
plex DNA secondary structures, which represent a roadblock 
for DNA replication (  Shen and Loeb, 2000  ;   Brosh et al., 2002  ). 
Third, WRN is required for fruitful recovery from replication 
fork arrest (  Pichierri et al., 2001  ;   Sakamoto et al., 2001  ;   Baynton 
et al., 2003  ). Furthermore, WRN has been recently found to inter-
act or colocalize with proteins involved either in the intra-S 
or replication checkpoint and is targeted by the replication 
checkpoint kinase ataxia telangiectasia and Rad3 related (ATR; 
  Baynton et al., 2003  ;   Pichierri et al., 2003  ;   Cheng et al., 2004  ; 
  Franchitto and Pichierri, 2004  ). 
  Fragile sites are replication-delayed genomic regions 
particularly sensitive to partial inhibition of DNA synthesis by 
aphidicolin (  Glover et al., 1984  ). Previous studies proposed 
that the stalling of replication forks may correlate with DNA 
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  In this study, we found that WRN was implicated in the re-
sponse to the partial inhibition of DNA synthesis induced by low 
doses of aphidicolin. Using cells from WS patients or fi  broblasts 
in which endogenous WRN was down-regulated by RNA inter-
ference, we have shown that the loss of functional WRN leads to 
common fragile site instability with or without aphidicolin treat-
ment. WRN helicase rather than exonuclease activity seems to 
play the main role in stabilizing fragile sites. Furthermore, we 
suggest that WRN and ATR act in a common pathway preventing 
accumulation of DNA gaps and breaks at common fragile sites. 
  Results 
  WRN accumulates into nuclear foci after 
aphidicolin-induced replication delay 
  It has been demonstrated that WRN is mainly located in the nu-
cleoli and relocalizes to nuclear foci after DNA damage or rep-
lication fork arrest (  Sakamoto et al., 2001  ;   Baynton et al., 2003  ; 
  Pichierri et al., 2003  ;   Otterlei et al., 2006  ). This subnuclear re-
distribution seems to be a general behavior of WRN in response 
to DNA damage or replication arrest. Thus, we wanted to verify 
whether WRN was relocalized into nuclear foci in response to 
partial inhibition of DNA replication. 
 Wild-type  fi  broblasts were exposed to 0.4     M  aphidicolin 
and fi  xed at different time points (  Fig. 1  ). Before fi  xation, cells 
were detergent-extracted to visualize only the chromatin-associated 
breaks and chromosomal rearrangements occurring at common 
fragile sites (  Arlt et al., 2003  ;   Schwartz et al., 2006  ). Although 
extensive knowledge of the molecular determinants underlying 
common fragile site instability is still missing, computational 
analysis performed on a subset of these genomic sequences has 
suggested that common fragile sites could be regions enriched 
in clusters of highly fl  exible ataxia telangiectasia sequences 
(  Mishmar et al., 1998  ;   Zlotorynski et al., 2003  ). These se-
quences show in silico the propensity to form stable secondary 
DNA structures that perturb replication, contributing to genome 
fragility. Very little is known about the molecular mecha-
nisms involved in their stability but it is thought that ATR and 
other proteins working in the response to replication stress 
are implicated (  Casper et al., 2002  ;   Arlt et al., 2004  ;   Howlett 
et al., 2005  ;   Musio et al., 2005  ). More recently, it has been pro-
posed that homologous recombination and, to a lesser extent, 
nonhomologous end joining are required for fragile site sta-
bility after aphidicolin-induced replication slowdown ( Schwartz 
et al., 2005  ). 
 These  fi  ndings led to the conclusion that chromosomal 
breakage occurring at fragile sites is the end result of in  correct 
recovery from replication fork stalling at these loci. Taking into 
account the fact that fork stalling is a very frequent and dangerous 
event that occurs naturally during normal DNA replication, com-
mon fragile sites may represent a useful means to study mecha-
nisms underlying replication fork recovery in vivo. 
  Figure 1.       WRN forms foci in response to aphidi  -
colin-induced replication slowdown.   (A) Colocal-
ization of WRN-positive nuclei with S phase cells. 
Wild-type ﬁ   broblasts were treated with 0.4      M 
aphidicolin for 24 h, pulse-labeled with 3      g/ml 
BrdU for 30 min before ﬁ  xation, and double immuno-
stained with      -WRN and      -BrdU as described in 
Immunoﬂ  uorescence. Bars, 5      m. (B) Percentage 
of cells showing WRN foci in response to 0.4      M 
aphidicolin (Aph) treatment (left) and percentage 
of BrdU-positive nuclei (right). Incorporation of 
BrdU was evaluated by immunoﬂ  uorescence using 
speciﬁ  c antibodies. Data are presented as means 
from three independent experiments. Error bars 
represent standard error.     307  WRN HELICASE AND FRAGILE SITES   •   PIRZIO ET AL.
  Cells lacking functional WRN show 
increased sensitivity to aphidicolin 
  To test the hypothesis that WRN plays a role in the maintenance 
of fragile site stability, we fi  rst investigated the sensitivity of 
WS cells to aphidicolin-induced replication slowdown. We ex-
posed wild-type and WS fi  broblasts to different concentrations 
of the drug and, 24 h later, metaphase chromosomes were col-
lected and scored for total gaps and breaks (  Fig. 2, A and B;   and 
Fig. S1, A and B, available at http://www.jcb.org/cgi/content/
full/jcb.200705126/DC1). A dose-dependent induction of chromo-
some gaps and breaks was observed in both cell lines, with WS 
WRN, the fraction that is thought to be localized at stalled replica-
tion forks. Aphidicolin-induced replication slowdown resulted in 
a marked relocalization of WRN into diffuse subnuclear foci 
(  Fig. 1 A  ) and the percentage of cells with WRN foci increased 
in a time-dependent manner, reaching     80% at 24 h (  Fig. 1 B  ). 
Interestingly, the percentage of nuclei with diffuse WRN foci 
matched the percentage of cells in S phase as demonstrated by 
BrdU incorporation ( Fig. 1, A and B ), which suggests that relocal-
ization is linked to replication inhibition induced by aphidicolin. 
Altogether, our results indicate that WRN is implicated in the 
response to replication slowdown induced by aphidicolin. 
  Figure 2.       WRN deﬁ  ciency leads to increased spontaneous and aphidicolin-induced DNA chromosomal aberrations.   (A) Mean overall chromosome gaps 
and breaks per cell in wild-type (wt) and WS cells. Cells were treated with different doses of aphidicolin (Aph) 24 h before harvest. Data are presented 
as means of three independent experiments. Asterisks indicate that the result is statistically signiﬁ  cant compared with the wild type; P   <   0.05 by   t   test. 
(B) Representative Giemsa-stained metaphase of WS ﬁ  broblasts treated with 0.2      M aphidicolin. Arrows indicate chromosomal aberrations. (C) Western blot-
ting probed with      -WRN showing the reduction in the WRN protein level in wild-type ﬁ  broblasts transfected with control siRNA or siRNAs directed against 
WRN and harvested 48 or 72 h after interference. Tubulin was used as loading control. (D) Mean overall chromosome gaps and breaks per cell in wild-type 
ﬁ  broblasts (mock), ﬁ  broblasts transfected with control siRNA, or ﬁ  broblasts in which WRN was abrogated by RNAi (WRN RNAi). Cells were treated with 
different doses of aphidicolin 24 h before being harvested. Data are presented as means of three independent experiments. Asterisks indicate that the result 
is statistically signiﬁ  cant compared with the wild type; P   <   0.05 by   t   test. Error bars represent standard error. (E) Representative Giemsa-stained metaphase 
of ﬁ  broblasts in which WRN was abrogated by RNAi and treated with 0.4      M aphidicolin. Arrows indicate chromosomal aberrations. Bars, 2.5      m.     JCB • VOLUME 180 • NUMBER 2 • 2008  308 
fi  broblasts showing an approximately sixfold increase in chromo-
somal damage in comparison to their wild-type counterparts. 
  Because there might be a compensation for WRN defi  -
ciency in cells derived from WS patients, we explored the effect 
of aphidicolin treatment in cells in which endogenous WRN 
was knocked down. Human wild-type fi  broblasts were trans-
fected with control siRNA and siRNAs directed against WRN 
and the reduction of WRN protein level was verifi  ed by Western 
blotting (  Fig. 2 C  ). Depletion of WRN resulted in an enhance-
ment of aphidicolin-induced chromosomal instability similar 
to that observed in WS cells (  Fig. 2, D and E  ). Interestingly, the 
abrogation of functional WRN increased spontaneous DNA gaps 
and breaks (  Fig. 2 D  ). Moreover, a higher chromosomal sensi-
tivity to aphidicolin was observed in a lymphoblastoid cell line 
(LCL) derived from a WS patient (Fig. S2 A, available at http://
www.jcb.org/cgi/content/full/jcb.200705126/DC1). 
 Altogether, these results reveal that WS cells are extremely 
sensitive to aphidicolin treatment and that the loss of WRN is 
responsible for chromosome instability. 
  WRN-deﬁ  cient cells have enhanced 
instability at common fragile sites 
  To determine whether the increase in chromosomal gaps and 
breaks after aphidicolin exposure observed in WS cells takes 
place at specifi  c DNA regions, we examined by FISH the induc-
tion of the most frequently expressed common fragile sites, 
FRA3B, FRA7H, and FRA16D, in wild-type and WS fi  bro-
blasts (Fig. S3, A and B, available at http://www.jcb.org/cgi/
content/full/jcb.200705126/DC1). At both doses of aphidicolin, 
WS cells showed a higher number of gaps and breaks occurring 
at fragile sites in comparison with control cells (  Fig. 3 A  ). Fragile 
site induction in WS cells increased in a dose-dependent manner 
and was about six times higher than in wild-type cells. The FRA3B 
site seems to be particularly sensitive, possibly because of the 
elevated percentage of hyperdamaged metaphases that were not 
included in the count (Fig. S4 A). 
 To  confi  rm these observations, we repeated the experi-
ment in wild-type fi  broblasts in which endogenous WRN was 
down-regulated. Cells transfected with WRN siRNA displayed 
enhanced expression of fragile sites after aphidicolin exposure 
(  Fig. 3 B  ). Interestingly, a higher level of fragile site induction 
was observed even in the absence of aphidicolin treatment. 
We established that although aphidicolin-induced total gaps 
and breaks per cell were more elevated in WS cells than in 
wild-type cells, the percentage of total breaks attributable to 
FRA7H and FRA16D was similar with or without the addition 
of the drug (  Table I  ). Fragile site expression was also analyzed 
in LCLs and the results were consistent with those obtained 
in fibroblasts (Fig. S2 B). Altogether, these findings provide 
  Figure 3.       Enhanced common fragile site expression in WRN-deﬁ  cient cells.   
(A) Frequency of fragile site FRA3B, FRA7H, and FRA16D expression in 
wild-type (wt) and WS cells. Cells were treated with two doses of aphidi-
colin (Aph) and harvested 24 h later. Frequency of fragile site induction is 
presented as the percentage of chromosome 3, 7, or 16 homologues with 
gaps and breaks at FRA3B, FRA7H, and FRA16D, respectively. Data are 
presented as means of three independent experiments. (B) Frequency of 
fragile site FRA3B, FRA7H, and FRA16D expression in wild-type ﬁ  broblasts 
(Mock), ﬁ  broblasts transfected with control siRNA, or ﬁ  broblasts in which 
WRN was abrogated by RNAi (WRN RNAi). In treated samples, differ-
ent doses of aphidicolin were added 48 h after interference and left until 
harvesting 24 h later. The frequency of fragile site induction is presented 
as the percentage of chromosome 3, 7, or 16 homologues with gaps and 
breaks at FRA3B, FRA7H, and FRA16D, respectively. Data are presented 
as means of three independent experiments. Asterisks indicate that the 
result is statistically signiﬁ  cant compared with the wild type; P   <   0.05 by 
  t   test. Error bars represent standard error.     
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genes by RNAi in wild-type fi  broblasts, we verifi  ed that the re-
duction in the corresponding protein levels (  Fig. 5 A  ) was not 
detrimental to cell growth at least within the period of the assay 
(not depicted). We then treated cells with 0.05 or 0.4    M aphidi-
colin for 24 h and harvested them for chromosome preparations. 
Metaphases were examined for total gaps and breaks and then 
for the expression of FRA7H and FRA16D. Aphidicolin in-
creased the levels of gaps and breaks in cells defi  cient of WRN 
or ATR compared with the control cells (  Fig. 5 B  ). However, the 
concomitant depletion of WRN and ATR did not result in more 
chromosome damage than single defi  ciencies and fragile site 
induction was similar in cells in which both WRN and ATR were 
down-regulated by RNAi either under unstressed conditions or 
after aphidicolin application (  Fig. 5, B and C  ). 
  These data support the conclusion that WRN and ATR par-
ticipate in a common pathway safeguarding fragile site stability. 
  Discussion 
  In this paper, we describe how WRN defi  ciency results in a 
great enhancement of chromosome aberrations and common 
fragile site expression after aphidicolin-induced replication slow-
down. Most importantly, we demonstrate that loss of WRN func-
tion induces accumulation of chromosome gaps and breaks that 
specifi  cally localize at common fragile sites even under unper-
turbed cell growth; i.e., in the absence of treatment. Consistently, 
exposure to aphidicolin at a dose that induces common fragile 
sites determines an extensive relocalization of WRN to nuclear 
foci in replicating cells. Finally, we present evidence that indi-
cates that the helicase activity of WRN but not its exonuclease 
function is essential to prevent common fragile site expression 
and that ATR and WRN act in a common pathway to stabilize 
such genomic regions. 
  Several pieces of evidence indicate that common fragile 
sites are genomic regions where DNA replication is slowed and 
eventually stalled at poorly defi  ned DNA structures ( Glover et al., 
1984, 2005  ;   Casper et al., 2002  ). The aphidicolin doses used in 
this study slow down replication but do not completely arrest 
DNA polymerases and are thought to interfere signifi  cantly only 
with replication of common fragile sites (  Glover et al., 1984  ). 
Thus, our fi  ndings strongly correlate WRN function with these 
naturally occurring replication fork stalling sites, which further 
supports the hypothesis that this RecQ helicase is crucial for 
genome integrity whenever replication forks stall, even during 
unperturbed cell growth. However, although WRN has been 
proposed to be involved in the rescue of stalled replication forks 
evidence that WRN infl  uences the stability of common fragile 
sites both during normal DNA synthesis and in response to rep-
lication perturbation. 
  WRN helicase activity is required for fragile 
site stability 
  To determine whether one or both WRN enzymatic activities 
could affect fragile site stability, we produced WS defective cell lines 
stably expressing wild-type WRN or mutant forms of WRN af-
fecting either helicase or exonuclease activity. Missense muta-
tions have been previously introduced in WRN to inactivate the 
exonuclease or helicase activity (  Gray et al., 1997  ;   Huang et al., 
1998  ;   Cheng et al., 2004  ). Western blotting analyses showed 
that the levels of WRN protein expressed in WS cells transfected 
with wild-type   WRN   cDNA (  Fig. 4 A  , WS  WRN )  and WRN  lack-
ing exonuclease (WRN-E84A) or helicase (WRN-K577M) activity 
were comparable to that of control cells (GM3675). Immuno-
fl  uorescence staining of WRN protein revealed the proper pat-
tern of subnuclear localization, i.e., mainly in the nucleoli under 
unperturbed conditions and diffused in the nucleoplasm after 
camptothecin-induced replication stress (  Fig. 4 B  ). Hypersensi-
tivity to camptothecin, a characteristic cellular phenotype of WS 
cells, was tested and, as expected (  Swanson et al., 2004  ), ex-
pression of wild-type WRN or missense mutant forms of WRN 
resulted in reduced cell death, reaching values similar to that of 
control cells (  Fig. 4 C  ). 
  In comparison with wild-type cells (WS  WRN  ), the ex-
pression of missense mutant forms of WRN protein in WS cells 
(WRN-E84A and WRN-K577M) led to a signifi  cant increase 
in chromosomal damage after aphidicolin exposure (  Fig. 4 D  ). 
However, FISH analyses performed on metaphases after 24 h of 
treatment indicated that the induction of FRA3B, FRA7H, and 
FRA16D was enhanced in a statistically signifi  cant manner only 
in WS and WRN-K577M cells (  Fig. 4 F  ). Thus, we conclude that 
the maintenance of common fragile site stability requires a WRN 
protein with intact helicase activity. 
  WRN and ATR regulate fragile site stability 
in a common pathway 
  It has been reported that the ATR replication checkpoint is cru-
cial for the maintenance of common fragile site stability after 
replication inhibition as well as under unperturbed conditions 
(  Casper et al., 2002  ). Because WRN is targeted by ATR upon 
replication stress (  Pichierri et al., 2003  ;   Otterlei et al., 2006  ), we 
investigated the link between WRN and ATR in the stabilization 
of fragile sites. After down-regulation of WRN, ATR, or both 
  Table I.       Fragile site expression in wild-type and WRN-deﬁ  cient (WRNi) cells   
Cell line Treatment Mean gaps and 
breaks per cell
Percentage of FRA7H 
loci with a break
Percentage of total 
breaks attributable to 
FRA7H
Percentage of 
FRA716D loci with a 
break
Percentage of total 
breaks attributable to 
FRA16D
    Wild type      APH 0.5 0 0 0 0
+APH 0.6 1 3.3 1.1 3.6
    WRNi      APH 1.3 8 12.3 7 10.7
+APH 2.2 16 14.5 13 11.8
APH, 0.05      M aphidicolin.JCB • VOLUME 180 • NUMBER 2 • 2008  310 
(  Mohaghegh et al., 2001  ;   Crabbe et al., 2004  ;   Multani and 
Chang, 2007  ). Furthermore, WRN is required in vitro to support 
DNA polymerase       in duplicating substrates forming G4 DNA 
from expanded triplet repeats (  Kamath-Loeb et al., 2001  ). Thus, 
WRN may function as an accessory helicase specifi  cally in-
volved in the resolution of those unusual DNA structures that 
can arise at common fragile sites as well as other genomic sites 
such as telomeres and could otherwise impede normal replication. 
In this context, WRN would exert a function similar to that 
of the yeast Rrm3 protein, a DNA helicase implicated in the 
maintenance of genome stability (  Ivessa et al., 2000  ;   Torres et al., 
2004b  ). Even though Rrm3 has an opposite polarity compared 
with WRN, Rrm3 yeasts show some features resembling WRN 
defi  ciency such as replication delay, replication fork pausing or 
collapse, accumulation of DNA breakage, and premature aging 
by either a recombinogenic or nonrecombinogenic pathway 
(  Ozgenc and Loeb, 2005  ), WRN exerted its protective role on a 
specifi  c subset of replicating regions. Our data suggest that 
WRN is most probably required specifi  cally at slow-replicating 
sites to prevent their instability. Of particular interest are the re-
sults demonstrating that WRN helicase rather than exonuclease 
activity plays a crucial role in the maintenance of common frag-
ile site stability. Indeed, these naturally occurring slow-replicating 
zones might be the only physiological targets of the WRN care-
taker function; the secondary structures thought to accumulate 
at these sites (  Zlotorynski et al., 2003  ;   Schwartz et al., 2006  ) 
could also represent potential in vivo substrates of WRN heli-
case activity. Previous studies have suggested that WRN heli-
case activity may effi  ciently resolve unusual DNA structures at 
telomeric sequences to facilitate replication fork progression 
  Figure 4.       Impaired WRN helicase activity is responsible for common fragile site instability.   (A) Western blotting analysis showing the expression of WRN 
protein in cells stably expressing wild-type WRN (WS  WRN  ) or missense mutant forms of WRN with impaired exonuclease (WRN-E84A) or helicase (WRN-
K577M) activity. GM3675 ﬁ  broblasts were used as a positive control. The membrane was probed with      -WRN. Tubulin was used as a loading control. 
(B) Subnuclear localization of WRN in response to camptothecin-induced replication stress. Indirect immunoﬂ  uorescence staining was achieved using the same 
antibody as in Western blotting. (C) Sensitivity of cells to camptothecin-induced replication stress. Cell death was evaluated by the trypan blue method as 
described in Cell death evaluation. The percentage of cell death was indicated for each dose of camptothecin. (D) Mean overall chromosome gaps and 
breaks per cell in WS cells, WS cells expressing mutant forms of exonuclease (WRN-E84A) or helicase (WRN-K577M) activity, and WS cells in which 
wild-type WRN was reintroduced (WS  WRN  ). Cells were exposed to different doses of aphidicolin (Aph) 24 h before harvest. Data are presented as means 
of three independent experiments. (E) Representative Giemsa-stained metaphases of WS ﬁ  broblasts (a), WS cells transfected with wild-type   WRN   cDNA 
(WS  WRN  ; b), or WRN lacking helicase (WRN-K577M; c) or exonuclease (WRN-E84A) activity (d), or treated with 0.2      M aphidicolin. Arrows indicate 
chromosomal aberrations. (F) Frequency of fragile site FRA3B, FRA7H, and FRA16D expression in WS, WRN-E84A, WRN-K577M, and WS  WRN   cells. 
Samples were treated with different doses of aphidicolin and left until harvesting 24 h later. Frequency of fragile site induction is presented as the percent-
age of chromosome 3, 7, or 16 homologues with gaps and breaks at FRA3B, FRA7H, and FRA16D, respectively. Data are presented as means of three 
independent experiments. Asterisks indicate that the result is statistically signiﬁ  cant compared with the wild type; P   <   0.05 by   t   test. Error bars represent 
standard error. Bars, 2.5      m.     311  WRN HELICASE AND FRAGILE SITES   •   PIRZIO ET AL.
in the stability of common fragile sites (  Schwartz et al., 2005  ), 
the function of WRN at these naturally occurring fork stalling sites 
could be unrelated to its proposed recombinogenic function. 
  Our results indicate that exonuclease defi  ciency leads to 
a signifi  cant enhancement of chromosome gaps and breaks at 
levels comparable to those observed in the absence of helicase 
activity. However, these aberrations are not localized at the three 
common fragile sites analyzed. A possible explanation for this is 
that some fragile sites may be more sensitive to the absence of the 
exonuclease activity of WRN than others. Alternatively, aphidi-
colin treatment could sensitize other fragile genomic regions 
to break in the absence of the exonuclease function of WRN. 
(  Ivessa et al., 2000  ;   Torres et al., 2004a,b  ;   Azvolinsky et al., 2006  ). 
Similarly, it has been proposed that Rrm3p is needed mainly to 
help fork progression by removing obstacles such as proteins or 
particular DNA structures at telomeres or along other diffi  cult-
to-replicate regions (  Ivessa et al., 2002  ,   2003  ;   Azvolinsky et al., 
2006 ;   Boule and Zakian, 2006  ). Interestingly, both WRN enzy-
matic activities are required for recombination-related functions, 
either after DNA damage (  Saintigny et al., 2002  ) or at telomere 
sequences in cells that are engaged in the alternative lengthening 
of telomere pathway (  Laud et al., 2005  ), whereas the helicase ac-
tivity seems to be suffi  cient to prevent instability at common 
fragile sites. Thus, even though recombination has been implicated 
  Figure 5.       The     effect of ATR and WRN down-regulation on fragile site expression.   (A) Western blotting analysis of protein depletion after transfection of 
wild-type cells with no siRNA (lane 1) or siRNAs directed against ATR (lane 2), WRN (lane 3), or both (lane 4). The membrane was probed ﬁ  rst with      -ATR 
and then stripped and reprobed with      -WRN, showing the reduction in the corresponding protein levels in wild-type ﬁ  broblasts transfected with no siRNA 
or siRNAs directed against WRN, ATR, or both and harvested 48 h after interference. Tubulin was used as loading control. (B) Mean overall chromosome 
gaps and breaks per cell in cells interfered with control siRNA or siRNAs against ATR and/or WRN. For site fragile induction, different doses of aphidicolin 
(Aph) were added 24 h before harvest. Data are presented as means of three independent experiments. For statistical analysis, single mutants are com-
pared with the double knockdown. (C) Frequency of gaps and breaks at speciﬁ  c fragile sites FRA7H and FRA16D in the wild type and ﬁ  broblasts depleted 
of ATR and/or WRN and treated for 24 h with different doses of aphidicolin. Fragile sites were identiﬁ  ed by FISH using probes speciﬁ  c to these sites as 
described in the FISH section. Frequency of fragile site induction is presented as the percentage of chromosome 7 or 16 homologues with gaps and breaks 
at FRA7H and FRA16D, respectively. Data are presented as means of three independent experiments. For statistical analysis, single mutants are compared 
with the double knockdown. Error bars represent standard error.     JCB • VOLUME 180 • NUMBER 2 • 2008  312 
fragile sites in Epstein-Barr virus  –  transformed lymphoblasts 
derived from WS patients, which are telomerase profi  cient and 
thus protected from telomere erosion. 
  In summary, this study provides additional insights into the 
mechanisms underlying common fragile site stability and sug-
gests that WRN helicase activity is a key factor in the maintenance 
of integrity of these specifi  c DNA regions. This supports the 
hypothesis that WRN may function in the resolution of problems 
arising in response to alterations in DNA replication and gives 
insights into the in vivo substrates of this genome caretaker protein. 
Failure to preserve fragile site stability may have a causative role 
in the chromosomal abnormalities observed in WS cells. 
  Materials and methods 
  Cell lines and culture conditions 
  Wild-type (9173675) and WS ﬁ  broblasts (AG11395) were obtained from 
Coriell Cell Repositories. The AG11395 cell line carries an Arg368 stop 
mutation that gives rise to a truncated protein. 
  Full-length cDNA encoding wild-type or missense mutant forms of 
WRN with inactive exonuclease (WRN-E84A) or helicase (WRN-K577M) 
activity (provided by J. Oshima, University of Washington, Seattle, WA) 
were subcloned into a pLXSP expression vector (provided by S. Soddu, 
Regina Elena Cancer Institute, Rome, Italy). The recombinant vectors were 
transfected into Phoenix packaging cells (provided by S. Soddu) by the 
standard Ca  2  PO  4   method and, 24 h later, WS cells (AG11395) were infected 
with retroviral supernatant. Puromycin-resistant colonies were isolated and 
Western blotting analyses were performed to assess the expression of 
WRN protein. 
  Fibroblasts were maintained in DME (Invitrogen) supplemented with 
10% FBS (Boehringer Mannheim). All cell lines were incubated at 37  °  C in 
a humidiﬁ  ed 5% CO  2   atmosphere. 
  Chemicals and treatments 
  Aphidicolin, camptothecin, and BrdU were obtained from Sigma-Aldrich. 
Aphidicolin was dissolved in DMSO as a stock solution (10 mg/ml) and 
stored at      20  °  C. Camptothecin was dissolved in DMSO and a stock solution 
(2.5 mM) was prepared and stored at   –  20  °  C. BrdU was dissolved in sterile 
PBS as a stock solution (3 mg/ml) and stored at      20  °  C. After treatments, 
cells were cultured in complete medium at 37  °  C until they were processed. 
  Immunoﬂ  uorescence 
  Cells grown on 22       22-mm glass coverslips were treated with aphidicolin 
and harvested at the indicated times. For WRN staining before ﬁ  xation, 
cells were subjected to in situ fractionation essentially as described previ-
ously (  Mirzoeva and Petrini, 2001  ), with the exception that the NaCl con-
centration used in the cytoskeleton buffer was 150 mM. Staining with 
rabbit polyclonals anti-WRN (1:500; Novus BioLabs) was performed for 2 h 
at RT in 1% BSA/PBS. Species-speciﬁ  c ﬂ  uorescein- or Texas red  –  conjugated 
secondary antibodies (Jackson ImmunoResearch Laboratories) were ap-
plied for 1 h at RT followed by counterstaining with 0.5      g/ml DAPI in 
DABCO. Secondary antibodies were used at a 1:500 dilution. Slides were 
analyzed with a microscope (Leica) equipped with a charge-coupled de-
vice camera (Photometrics). Images were acquired as grayscale ﬁ  les using 
the Metaview software (MDS Analytical Technologies) and then processed 
using Photoshop (Adobe). For each time point, at least 200 nuclei were ex-
amined by two independent investigators and foci were scored at 100     . 
Only nuclei showing more than ﬁ  ve bright foci were counted as positive. 
Parallel samples incubated with either the appropriate normal serum or 
only with the secondary antibody conﬁ  rmed that the observed ﬂ  uorescence 
pattern was not attributable to artifacts. 
  Fragile site induction and slide preparation 
  Fragile sites were induced by treating cells with different concentrations of 
aphidicolin (0.05, 0.2, and 0.4      M). Cell cultures were incubated with 
0.2      g/ml colcemid at 37  °  C for 3 h until harvesting. Cells for metaphase 
preparations were collected according to standard procedure. In brief, the 
cellular pellet was resuspended in prewarmed hypotonic solution (0.075 M 
KCl in distilled water) and incubated at 37  °  C for 18 min followed by multi-
ple changes of ﬁ  xative solution (3:1 methanol/acetic acid). Cell suspen-
sion was dropped onto cold, wet slides to make chromosome preparations. 
Indeed, several genomic regions that are not classifi  ed as com-
mon fragile sites have the potential to undergo breakage, such as 
ataxia telangiectasia  –  rich palindromic regions or closely spaced 
Alu sequences that can form hairpin structures (  Freudenreich, 
2007 ). Interestingly, correct repair of double strand breaks arising at 
Alu-formed hairpins requires the nuclease activity of the MRE11 
complex (  Lobachev et al., 2002  ). Because it has been reported 
that WRN and the MRE11 complex might cooperate in response to 
DNA damage ( Cheng et al., 2004 ;  Franchitto and Pichierri, 2004 ), 
it is tempting to speculate that the nuclease activities of WRN and 
MRE11 could regulate breakage at noncommon fragile sites un-
der replication stress. 
  Furthermore, we found that WRN regulates fragile site 
stability, acting in a pathway associated with ATR-mediated 
checkpoint response. Our analysis reveals that WRN defi  ciency 
recapitulates ATR defects in terms of fragile site instability ei-
ther upon aphidicolin treatment or under unperturbed conditions. 
According to the model proposed by   Casper et al. (2002)  , ATR 
is activated after replication stress to block cell cycle progres-
sion to stabilize and then rescue stalled replication forks, pro-
moting the restart of DNA synthesis. Similarly, WRN appears to 
be essential for fruitful rescue from replication fork arrest ( Pichierri 
et al., 2001  ;   Sakamoto et al., 2001  ;   Baynton et al., 2003  ) and 
is targeted for phosphorylation by ATR upon replication arrest 
(  Pichierri et al., 2003  ;   Otterlei et al., 2006  ). Hence, it is likely 
that WRN helicase could be required to collaborate with ATR in 
the recovery of stalled forks at fragile sites, possibly resolving 
aberrant DNA structures arising as a consequence of the charac-
teristic DNA sequence of these regions. It is noteworthy that 
ATR defi  ciency affects not only the stability of stalled forks but 
also the inhibition of DNA synthesis (  Abraham, 2001  ), whereas 
loss of WRN function does not infl  uence the checkpoint branch 
that triggers cell cycle progression after replication stress ( Franchitto 
and Pichierri, 2004  ). Thus, it is conceivable that the common 
function of WRN and ATR is unrelated to cell cycle arrest and 
more strictly correlated to the branch of the replication check-
point involved in the stabilization of stalled forks. 
 It has been recently shown that instability at common frag-
ile sites is a hallmark of early precancerous lesions (  Gorgoulis 
et al., 2005  ) and it is widely accepted that most gross chromo-
somal rearrangements accumulating in solid tumors originate 
from fragile sites (  Arlt et al., 2006  ). WS is a cancer-prone and 
chromosome fragility syndrome characterized by gross chromo-
somal rearrangements (  Martin and Oshima, 2000  ;   Oshima, 2000  ). 
Because instability of common fragile sites is readily detected 
in cells depleted of WRN even under normal division, it is pos-
sible that chromosomal instability observed in WS cells could 
correlate with breaks accumulating at these sites. However, a re-
cent study suggests that most of the chromosomal abnormalities 
arising in WS cells could be related to erosion of telomeric se-
quences (  Crabbe et al., 2007  ). These hypotheses are not neces-
sarily incompatible. Indeed, both the common fragile site and 
telomere stabilities that might require the helicase activity of 
WRN to clear the way for the replisome and chromosomal re-
ar  rangements observed in WS are most likely derived from a 
common protective mechanism at telomeric and nontelomeric 
sequences. Consistently, we also observe instability at common 313  WRN HELICASE AND FRAGILE SITES   •   PIRZIO ET AL.
  All LCLs were routinely maintained in exponential growth in RPMI 
1640 medium (Invitrogen) supplemented with 12% heat-inactived fetal 
calf serum (Boehringer Mannheim) by a daily dilution to 3.5       10 
5   cells 
per milliliter. 
  Online supplemental material 
  Fig. S1 contains images of metaphase chromosomes showing chromo-
somal aberrations induced by aphidicolin in wild-type and WS ﬁ  broblasts. 
Fig. S2 shows additional data conﬁ  rming enhanced expression of fragile 
sites after aphidicolin treatment in a WS lymphoblast cell line. Fig. S3 shows 
images of metaphase chromosomes expressing fragile sites induced by 
aphidicolin in wild-type and WS ﬁ  broblasts. Fig. S4 shows the percentage 
of hyperdamaged cells in WS ﬁ  broblasts after aphidicolin treatment. Online 
supplemental material is available at http://www.jcb.org/cgi/content/
full/jcb.200705126/DC1. 
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